Using Harm Reduction to Mitigate Opioid Addition in Patients With Care

Using Harm Reduction to Mitigate Opioid Addition in Patients With Care

Publication date: Apr 12, 2019

Harm reduction, a feasible approach to managing opioid misuse/diversion in oncology patients, was discussed in a presentation at the Oncology Nursing Society (ONS) 44th Annual Congress, held in Anaheim, California.

In the context presented by Dr McNally, harm reduction is not an attempt at abstinence, nor is it an active treatment for addiction, which is beyond the scope of care provided by oncology advance practice providers APPs – in this context, nurse practitioners and physician assistants.

Prescribing practices to consider include use of prescription drug monitoring program (PDMP), have patients sign a controlled medicine management contract and complete a pain diary, limit prescription quantity, decrease the pill load (sustained vs immediate release), pill counts, and urine toxicology screens.

With education specific to addiction and harm reduction strategies, APPs are well-positioned to implement these tactics and make a positive impact on patient outcomes.

Concepts Keywords
Abstinence Addiction behavioral disorder
Addiction Pain
AIDS Health
Anaheim Psychoactive drugs
ANP RTT
Behavioral Disorder Articles
Brain Morphine
California Euphoriants
Columbus Substance abuse
Congress Substance dependence
Epidemic Opioid use disorder
Harm Reduction Harm reduction
Hematology Heroin
Nurse Practitioners
Ohio
Oncology
Opioid
Opioid Addiction
Opioid Epidemic
Opioids
Pain
PhD
Physician Assistants
Prescription Drug
Sustained Release
Toxicology
Urine

Semantics

Type Source Name
disease MESH cancer
disease DOID cancer
gene UNIPROT ARID1A
gene UNIPROT LARGE1
disease MESH acquired immune deficiency syndrome
disease DOID acquired immune deficiency syndrome
gene UNIPROT PDC
gene UNIPROT NPPA
gene UNIPROT CTSB
gene UNIPROT DBF4
gene UNIPROT EHD1
gene UNIPROT IK
gene UNIPROT DYRK3
disease MESH multiple
pathway BSID Release
gene UNIPROT IMPACT
gene UNIPROT ANP32B
gene UNIPROT TNFSF13

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *